AbCellera Biologics Inc.
ABCL
Rang in aandelen
#4050
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Aandeelprijs
$12.29
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$3.98B
Verandering (1 dag)
4.95%
Verandering (1 jaar)
124.68%
Land
CA
Handel AbCellera Biologics Inc. (ABCL)
Categorie
Healthcare
Koersgeschiedenis voor AbCellera Biologics Inc. (ABCL)
Hoogste slotkoers: $12.67 op 2026-10-01
Laagste slotkoers: $45.73 op 2020-12-01
Laagste slotkoers: $45.73 op 2020-12-01
Koersgeschiedenis van AbCellera Biologics Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 69.44% |
| 2025 | 23.13% |
| 2024 | -44.83% |
| 2023 | -50.84% |
| 2022 | -25.40% |
| 2021 | -68.67% |
| 2020 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
